G1 Therapeutics Inc (GTHX) Stock
GTHX is no longer traded. G1 Therapeutics was delisted from the Nasdaq in September 2024.
Prices on this page are historical; the last trade was September 13, 2024 at $7.15.
G1 Therapeutics stock price history
GTHX final trading statistics
- Final close
- $7.15
- Final trading day
- Sep 13, 2024
- Market cap at delisting
- $377.22M
- Shares outstanding
- 52.76M
- Final 52-week range
- $1.08 – $7.19
- Avg. volume (final 3 mo.)
- 2,154,410
- All-time high (split-adj.)
- $67.97 · Sep 2018
- All-time low (split-adj.)
- $1.12 · Oct 2023
- Return since IPO
- -52.3%
- Beta
- 1.68
- Book value / share
- $0.47
- Price / book
- 15.31
G1 Therapeutics annual financials
| Fiscal year | Revenue | Net income | EPS |
|---|---|---|---|
| FY2023 | $82.51M | -$48.0M | -$0.95 |
| FY2022 | $51.30M | -$147.6M | -$3.39 |
| FY2021 | $31.48M | -$148.4M | -$3.53 |
| FY2020 | $45.28M | -$99.3M | -$2.63 |
| FY2019 | $2.14M | -$122.1M | -$3.26 |
Last five fiscal years reported before the delisting; fiscal year ending December. EPS is adjusted (non-GAAP) EPS as reported. Source: company filings via EODHD.
About G1 Therapeutics Inc
G1 Therapeutics, Inc., a commercial-stage biopharmaceutical company, engages in the discovery, development, and commercialization of small molecule therapeutics for the treatment of patients with cancer in the United States. The company offers COSELA, which helps to decrease incidence of chemotherapy-induced myelosuppression in adult patients treated with a platinum/etoposide-containing regimen or topotecan-containing regimen for extensive stage small cell lung cancer. It is also developing Trilaciclib that is in Phase 3 clinical trial for 1L metastatic triple negative breast cancer (mTNBC); and Phase 2 clinical trial as an antibody-drug conjugate combination trial in mTNBC, as well as completed Phase 2 clinical trial for Neoadjuvant TNBC and 1L Bladder cancer. The company has a license agreement with Genor Biopharma Co. Inc. for the development and commercialization of lerociclib using an oral dosage form to treat various indication in humans; Incyclix for the development and commercialization of a CDK2 inhibitor for all human and veterinary uses; and Simcere Pharmaceutical Co., Ltd for the development and commercialization of trilaciclib in all indications. G1 Therapeutics, Inc. was incorporated in 2008 and is headquartered in Research Triangle Park, North Carolina.
G1 Therapeutics stock FAQ
What happened to G1 Therapeutics stock?
G1 Therapeutics stock was delisted from the Nasdaq. Its final close was $7.15 on September 13, 2024.
Is GTHX stock still trading?
No. GTHX was delisted from the Nasdaq in September 2024 and no longer trades on a U.S. exchange.
What was the last price of GTHX stock?
GTHX closed at $7.15 on its final trading day, September 13, 2024, for a market value of about $377.22M.
What were G1 Therapeutics's revenue and earnings in its last full fiscal year?
G1 Therapeutics reported revenue of $82.51M and net income of -$48.0M in fiscal 2023, its last full year as a public company.
When did G1 Therapeutics go public?
G1 Therapeutics Inc stock began trading on May 17, 2017.